• 1
    He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64–0802. Clin Pharmacokinet 1999; 37: 47184.
  • 2
    Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3: 22936.
  • 3
    Huet PM, Villeneuve JP, Fenyves D. Drug elimination in chronic liver disease. J Hepatol 1997; 26(Suppl 2): 6372.
  • 4
    FDA Draft: Guidance for Industry, November 1999: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling.
  • 5
    Wiltshire H, Wiltshire B, Citron A, et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64–0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatographr B Biomed Sci Appl 2000; 745: 37388.
  • 6
    Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 101624.